Introduction {#fsn3374-sec-0001}
============

Epidemiological, human intervention, and mechanistic trials have shown that polyphenol‐rich foods, often found in a diet rich in fruits and vegetables, may have protective effects against chronic degenerative diseases linked to oxidative stress and reactive oxygen species (ROS)‐mediated cell damage (Cassidy et al. [2011](#fsn3374-bib-0006){ref-type="ref"}; Wedick et al. [2012](#fsn3374-bib-0040){ref-type="ref"}; Del Rio et al. [2013](#fsn3374-bib-0011){ref-type="ref"}). Flavonoids and other phenolic compounds in these foods are bioactive health components that are likely responsible for these effects. The North American cranberry (*Vaccinium macrocarpon* Ait. Ericaceae) is of growing public interest as a functional food because of potential health benefits linked to the high content of bioactive flavonoids in the fruit, including proanthocyanidins, flavonols such as quercetin and myricetin and anthocyanins. In fact, cranberry ranks high among fruit in both antioxidant quality and quantity (Vinson et al. [2001](#fsn3374-bib-0037){ref-type="ref"}; Gu et al. [2004](#fsn3374-bib-0018){ref-type="ref"}; Côté et al. [2010](#fsn3374-bib-0008){ref-type="ref"}), and contain a higher amount of total phenols per serving (507--709 mg gallic acid equivalents/100 g) than other common fruits including blueberries (258--531 mg/100 g), apples (185--347 mg/100 g), and red grapes (175--370 mg/100 g) (Wu et al. [2004](#fsn3374-bib-0043){ref-type="ref"}). Cranberries, in powder, extract or juice, have been reported to be beneficial for helping prevent urinary tract infections (Wang et al. [2012](#fsn3374-bib-0038){ref-type="ref"}; Blumberg et al. [2013](#fsn3374-bib-0005){ref-type="ref"}; Foxman et al. [2015](#fsn3374-bib-0017){ref-type="ref"}), oxidative stress and cardiometabolic risk factors such as reducing C‐reactive protein and lowering blood pressure (Basu et al. [2011](#fsn3374-bib-0004){ref-type="ref"}; Dohadwala et al. [2011](#fsn3374-bib-0014){ref-type="ref"}; Novotny et al. [2015](#fsn3374-bib-0031){ref-type="ref"}). As cranberry is a natural food product and not a drug, the effect seen is often mild but that is consistent with the recommendation for a food with health components that is consumed as part of a healthy balanced lifestyle.

In vitro evidence has shown the antioxidant potential of cranberry phenolic compounds including protection of human microvascular endothelial cells against ROS, and HepG2 cells from inflammatory insults and reduced glycation (Caton et al. [2010](#fsn3374-bib-0007){ref-type="ref"}; Crozier et al. [2010](#fsn3374-bib-0009){ref-type="ref"}; Liu et al. [2011](#fsn3374-bib-0024){ref-type="ref"}; Watson et al. [2014](#fsn3374-bib-0039){ref-type="ref"}; Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}). A recent publication also showed the bioavailability and bioactivity of cranberry phenolics and metabolites from consuming cranberry juice beverage (McKay et al. [2015](#fsn3374-bib-0029){ref-type="ref"}). The protective effect of these compounds may be related to their function in sequestering ROS and/or maintaining the cell components in their correct redox state, but emerging findings indicate that natural compounds may act by increasing the endogenous antioxidant defense potential through regulation of cell signaling pathways (Seeram et al. [2004](#fsn3374-bib-0032){ref-type="ref"}; Stevenson and Hurst [2007](#fsn3374-bib-0035){ref-type="ref"}; Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}). The objective of this study is to examine the anti‐inflammatory activity of cranberry phenolic compounds in two different cranberry powders (90 MX and CE) by looking at changes in gene expression using human monocytic cells lines.

Material and Methods {#fsn3374-sec-0002}
====================

Chemicals {#fsn3374-sec-0003}
---------

Cranberry juice powder and extract were obtained from Ocean Spray Cranberries (Lakeville‐Middleboro, MA; for chemical analysis see Table [1](#fsn3374-tbl-0001){ref-type="table-wrap"} and reference \[Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}\]). Cranberry juice powder (90MX) was prepared from the juice of mature berries of the commonly cultivated cranberry plant (*Vaccinium macrocarpon*). Cranberry juice processing consists of the milling and pressing of the berries after a hot (50°C for 1 h) commercial pectinase maceration. 90MX was then prepared by spray drying cranberry concentrate with magnesium hydroxide as the carrier and tri‐calcium phosphate as an anti‐caking agent. The powder is fine, free‐flowing and rosy red in color, and contains approximately 90% cranberry solids. The cranberry extract (CE) powder is a water‐soluble, phenolic‐rich extract of cranberry utilizing a proprietary resin separation process. CE was standardized to 55% proanthocyanidin (PAC) content on a dry weight basis as analyzed by a modified 4‐dimethylaminocinnamaldehyde (DMAC) method (Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}). Finally, 100 mg/mL stock solutions of 90MX and CE were prepared in Dimethylsulfoxide (DMSO) for cell treatment. All media components and fetal bovine serum (FBS) were purchased from Gibco BRL/Life Technologies (Carlsbad, CA). Phorbol 12‐myristate 13‐acetate (PMA), used to differentiate THP‐1 cells, was purchased from Sigma Chemical Company (St. Louis, MO). All other chemicals and reagents were of highest quality available.

###### 

Content of phenolic compounds and other major components in cranberry juice and extract powders

                                                            Cranberry juice powder (90MX, mg/100 g)   Cranberry extract powder (CE, mg/100 g)   Enrichment (CE/90MX)[c](#fsn3374-note-0005){ref-type="fn"}
  --------------------------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------------------------
  Proanthocyanidins                                                                                                                             
  By OS‐DMAC method[a](#fsn3374-note-0003){ref-type="fn"}   2800                                      51,600                                    18.4
  By BL‐DMAC method[b](#fsn3374-note-0004){ref-type="fn"}   653                                       15,000                                    23.0
  Organic acids                                                                                                                                 
  Citric acid                                               14,200                                    2850                                      0.2
  Malic acid                                                8510                                      1660                                      0.2
  Quinic acid                                               13,500                                    2040                                      0.2
  Galacturonic acid                                         3300                                      78.4                                      0.0
  Sugars                                                                                                                                        
  Glucose                                                   31,300                                    4700                                      0.2
  Fructose                                                  8120                                      1100                                      0.1
  Anthocyanins                                                                                                                                  
  Cyanidin‐3‐arabinoside                                    33.8                                      420                                       12.4
  Cyanidin‐3‐galacoside                                     41.7                                      508                                       12.2
  Cyanidin‐3‐glucose                                        1.3                                       25.4                                      19.5
  Peonidin‐3‐arabinoside                                    17.3                                      239                                       13.8
  Peonidin‐3‐galactose                                      41.9                                      530                                       12.6
  Peonidin‐3‐glucoside                                      3.0                                       36.6                                      12.2
  Phenolic acids                                                                                                                                
  Benzoic acid                                              84.5                                      2550                                      30.2
  Salicylic acid                                            0.6                                       13.4                                      22.3
  Protocatechuic acid                                       15.6                                      120                                       7.7
  Gallic acid                                               4.2                                       25.8                                      6.1
  Vanilic acid                                              4.9                                       85.4                                      17.4
  *t*‐Cinnamic acid                                         7.7                                       72.8                                      9.5
  *p*‐Coumaric acid (4‐hydroxycinnamic acid)                30.2                                      436                                       14.4
  Caffeic acid (3,4‐dihydroxycinnamic acid)                 3.0                                       50.5                                      16.8
  Ferulic acid (3‐methoxy‐4‐hydroxycinnamic acid            0.9                                       54.7                                      60.8
  Chlorogenic acid                                          22.8                                      793                                       34.8
  Ellagic acid                                              1.3                                       2.2                                       1.7
  Flavon‐3‐ols                                                                                                                                  
  Catechin                                                  8.0                                       43.3                                      5.4
  Epicatechin                                               31.7                                      2.2                                       0.1
  Flavonols                                                                                                                                     
  Quercetin                                                 37.3                                      404                                       10.8
  Quercitrin (quercetin‐3‐*O*‐rhamnoside                    20.8                                      527                                       25.3
  Hyperoside (quercitin‐3‐*O*‐galactoside)                  53.1                                      2720                                      51.2
  Myricetin                                                 40.5                                      657                                       16.2
  Myricetrin (myrocetin‐3‐*O*‐rhamnoside)                   7.6                                       125                                       16.4
  Total phenolic by Folin‐Ciocalteu method (GAE)            2600                                      45,000                                    17.3

From Martín et al. ([2015](#fsn3374-bib-0028){ref-type="ref"}).

Expressed in milligram (mg) of cranberry‐specific PACs equivalents per 100 g of powder.

Expressed in milligram (mg) of procyanidine A‐2 equivalents per 100 g of powder.

Enrichment is the ratio of each component in the CE extract relative to that of 90MX.
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Cell culture and treatment {#fsn3374-sec-0004}
--------------------------

THP‐1 (*Homo sapiens* monocyte) cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD) and cultured in RPMI 1640 with 10% heat inactivated FBS, 50 *μ*mol/L 2‐mercaptoethanol, 1 mmol/L sodium pyruvate, 100 U/mL penicillin and 100 *μ*g/mL streptomycin. These cells were seeded in 24‐well plates at a density of 3 × 10^5^/well and differentiated into macrophages with 100 nmol/L PMA (Sigma) for 48 h. For in vitro treatment experiments, THP‐1 cells were grown to 75% confluency and treated with 90MX or CE (0, 25, 50, 100 *μ*g dry weight/mL media, heretofore listed as *μ*g/mL). Sixteen hrs after treatment, the cells will be stimulated with 10 ng/mL LPS for 6 h.

RNA extraction, reverse transcription, real‐time PCR {#fsn3374-sec-0005}
----------------------------------------------------

Total RNA was isolated by Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer\'s instructions. The total RNA was reverse transcribed, using the ABI High Capacity cDNA archive kit (Applied Biosystems, Foster City, CA). Standard curves were made using serial dilutions from pooled cDNA samples. Real‐time polymerase chain reaction (PCR) was performed with the use of the SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer\'s protocol and amplified on the ABI Prism 7000 Sequence Detection System. Primers are listed in Table [2](#fsn3374-tbl-0002){ref-type="table-wrap"}.

###### 

Primer sequences used for quantitative real‐time PCR

  Gene      Forward primer            Reverse primer
  --------- ------------------------- -------------------------
  18S       ACCCGTTGAACCCCATTCGTGA    GCCTCACTAAACCATCCAATCGG
  ABCG2     ACGAACGGATTAACAGGGTCA     CTCCAGACACACCACGGAT
  CAT       TGTTGCTGGAGAATCGGGTTC     TCCCAGTTACCATCTTCTGTGTA
  CCNL2     GTACTCCGGGGTGCTCATC       GAGGTCGGTCTCTGTGTCG
  COX2      CGGTGTTGAGCAGTTTTCTCC     AAGTGCGATTGTACCCGGAC
  CSF2      TCCTGAACCTGAGTAGAGACAC    TGCTGCTTGTAGTGGCTGG
  HERC5     GGTGAGCTTTTTGCCTGGG       TTCTCCGGCAGAAATCTGAGC
  IFIT1     GCGCTGGGTATGCGATCTC       CAGCCTGCCTTAGGGGAAG
  IFIT3     AGAAAAGGTGACCTAGACAAAGC   CCTTGTAGCAGCACCCAATCT
  IL‐1*α*   CTCCCAATCTCCATTCCCAA      CGTAAGGCCTCAGCCAGAAG
  IL6       GCCACTCACCTCTTCAGAACG     CCGTCGAGGATGTACCGAATT
  MSR1      GCAGTGGGATCACTTTCACAA     AGCTGTCATTGAGCGAGCATC
  MT1F      TCCTGCAAGAAGAGCTGCTG      ACTTCTCTGACGCCCCTTTG
  OAS1      TGTCCAAGGTGGTAAAGGGTG     CCGGCGATTTAACTGATCCTG
  SLC7A11   TCTCCAAAGGAGGTTACCTGC     AGACTCCCCTCAGTAAAGTGAC
  SOD1      GGTGTGGCCGATGTGTCTAT      CCTTTGCCCAAGTCATCTGC
  TNFA      ATCAATCGGCCCGACTATCTC     TGGATGTTCGTCCTCCTCACA
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Microarray experiments and statistical analysis {#fsn3374-sec-0006}
-----------------------------------------------

THP‐1 cells were treated with CE or 90MX at 100 *μ*g/mL or control (DMSO, 0.1% v/v) for 16 h followed by stimulation with LPS for 6 h. RNA was extracted, using Qiagen RNeasy and quality assessed by RNA Nano Chips on the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Each sample was labeled using the Affymetrix IVT Express Kit according to the manufacturer\'s protocol. The GeneChip Human Genome U133A 2.0 (Affymterix, Santa Clara, CA), representing 14,500 well‐characterized genes, was hybridized with the labeled RNA using GeneChip Hybridization Wash and Stain Kit (\#702232) in the Affymetrix GeneChip Hybridization Oven 640, according to the manufacturer\'s instructions. Following hybridization, the arrays were washed and stained using the Affymetrix GeneChip Fluidics Station 450 according to the manufacturer\'s protocol and scanned using the GeneChip Scanner 3000 7G. The scanned image file (DAT) and the intensity data (CEL) was imported into ArrayStar (DNASTAR, Inc., Madison, WI). The Robust Multi‐array Average (RMA) was used to normalize the data. The nine slides were grouped based on treatment and Student *t*‐test with asymptotic *P*‐value and Benjamini--Hochberg multiple corrections was performed comparing CE versus DMSO and 90MX versus DMSO. At a *P*‐value of 0.05 and a twofold change, a total of 236 entities were significantly regulated by CE while there were no genes that met the criteria for 90MX. The group of genes was examined by hierarchical clustering using complete linkage analysis of the normalized data (JMP 7.0; SAS Institute, Cary, NC). Gene Ontology (GO) and pathway analysis was performed, using Ingenuity Pathway Analysis (Qiagen, Redwood City, CA).

Statistical analysis {#fsn3374-sec-0007}
--------------------

One‐way analysis of variance, followed by Dunnett\'s post hoc test, was used to test the difference between treatments (*P* \< 0.05). The values were expressed as mean ± SEM. All data analyses were performed by JMP 7.0 (SAS Institute) and data plotted by Prism 5.01 (GraphPad Software, Inc., San Diego, CA).

Results {#fsn3374-sec-0008}
=======

Regulation of inflammation‐related genes in THP‐1 cells {#fsn3374-sec-0009}
-------------------------------------------------------

The ability of CEs to regulate proinflammatory gene expression in THP‐1 cells was examined using an LPS‐challenge model (Lee et al. [2009](#fsn3374-bib-0022){ref-type="ref"}; Zhang et al. [2010](#fsn3374-bib-0046){ref-type="ref"}). A single concentration of each extract (100 *μ*g/mL) was examined; there was no sign of overt toxicity at this dose (data not shown). The 90MX powder had no effect on expression of interleukin‐1*α* (IL‐1*α*), interleukin‐6 (IL6), tumor necrosis factor‐*α* (TNF*α*), catalase (CAT), cyclooxygenase‐2 (COX2) or superoxide dismutase 1 (SOD1) mRNA (Fig. [1](#fsn3374-fig-0001){ref-type="fig"}). The CE extract at this dose resulted in a significant increase in IL‐6 mRNA (2.5‐fold) with decreased expression of TNF*α*, CAT and SOD1 mRNA (1.6, 1.5 and 1.8‐fold, respectively) relative to the vehicle control. The pattern of gene expression, with several LPS‐induced genes being repressed while others are either unaffected or augmented, suggests an atypical mechanism of action and prompted a more comprehensive examination of mRNA concentration.

![Regulation of inflammation‐related genes by cranberry extracts in THP‐1 cells. Cells were treated and RNA extracted as described in Materials and Methods. Gene expression following treatment with DMSO (0.1% v/v),CE or 90MX (100 *μ*g/mL) is expressed relative to a housekeeping gene (18S) and normalized to vehicle control (DMSO). Asterisks denote significantly different than control (*P* \< 0.05, *n* = 3, bars represent mean and SEM).](FSN3-5-148-g001){#fsn3374-fig-0001}

Comprehensive analysis of gene expression {#fsn3374-sec-0010}
-----------------------------------------

The design of the present experiments was aimed to understand the anti‐inflammatory effects of cranberry polyphenol extracts to identify sensitive biomarkers for subsequent studies and to begin understanding their potential mechanism of action. The THP‐1 monocytes were treated with CE or 90MX at 100 *μ*g/mL for 16 h, followed by stimulation with LPS and the RNA was used to examine gene expression by high‐density microarray. A total of 236 genes were significantly regulated by CE with a twofold change (Table S1 and Fig. [2](#fsn3374-fig-0002){ref-type="fig"}) with 64 genes reaching a threefold threshold (Table [3](#fsn3374-tbl-0003){ref-type="table-wrap"}). There were no significant changes using these same criteria with the 90MX extract. A majority of the genes (78%) were repressed by CE; Metallothionein 1F (MT1F) mRNA was increased fivefold while interferon‐induced protein with tetratricopeptide repeats 5 (IFIT5) was reduced 10‐fold relative to the DMSO‐treated group.

![Comprehensive analysis of gene expression. Analysis of gene expression by high‐density microarrays was performed by microarrays as described in Material and Methods. Average expression values (*n* = 3 arrays per group) were exported to JMP (SAS Institute, Cary NC) and hierarchical clustering performed. Data were expressed relative to the DMSO‐treated group with green representing a decrease and red an increase relative to control (depicted as white).](FSN3-5-148-g002){#fsn3374-fig-0002}

###### 

Genes significantly regulated by cranberry extracts (threefold, *P* \< 0.05)

  Probe set ID   Gene symbol   Gene title                                                                                      90MX   CE
  -------------- ------------- ----------------------------------------------------------------------------------------------- ------ ------
  213629_x\_at   MT1F          Metallothionein 1F                                                                              0.80   4.84
  211906_s\_at   SERPINB4      Serpin peptidase inhibitor, clade B (ovalbumin), member 4                                       0.70   4.47
  210524_x\_at   MT1F          Metallothionein 1F                                                                              0.81   4.10
  212859_x\_at   MT1E          Metallothionein 1E                                                                              0.75   3.87
  220322_at      IL36G         Interleukin 36, gamma                                                                           0.72   3.56
  203213_at      CDK1          Cyclin‐dependent kinase 1                                                                       0.89   0.33
  210764_s\_at   CYR61         Cysteine‐rich, angiogenic inducer, 61                                                           0.87   0.33
  203725_at      GADD45A       Growth arrest and DNA‐damage‐inducible, alpha                                                   0.94   0.32
  207386_at      CYP7B1        Cytochrome P450, family 7, subfamily B, polypeptide 1                                           1.05   0.32
  211668_s\_at   PLAU          Plasminogen activator, urokinase                                                                1.04   0.32
  218662_s\_at   NCAPG         Non‐SMC condensin I complex, subunit G                                                          0.91   0.32
  214453_s\_at   IFI44         Interferon‐induced protein 44                                                                   0.57   0.31
  204747_at      IFIT3         Interferon‐induced protein with tetratricopeptide repeats 3                                     0.63   0.31
  203362_s\_at   MAD2L1        MAD2 mitotic arrest deficient‐like 1 (yeast)                                                    0.94   0.31
  219209_at      IFIH1         Interferon induced with helicase C domain 1                                                     0.80   0.31
  202127_at      PRPF4B        Pre‐mRNA processing factor 4B                                                                   0.56   0.30
  201291_s\_at   TOP2A         Topoisomerase (DNA) II alpha 170 kDa                                                            0.96   0.30
  218883_s\_at   CENPU         Centromere protein U                                                                            0.74   0.30
  213226_at      CCNA2         Cyclin A2                                                                                       0.80   0.29
  202508_s\_at   SNAP25        Synaptosomal‐associated protein, 25 kDa                                                         0.51   0.29
  209969_s\_at   STAT1         Signal transducer and activator of transcription 1, 91 kDa                                      0.80   0.29
  210559_s\_at   CDK1          Cyclin‐dependent kinase 1                                                                       0.90   0.29
  211597_s\_at   HOPX          HOP homeobox                                                                                    0.99   0.29
  216442_x\_at   FN1           Fibronectin 1                                                                                   1.00   0.28
  206513_at      AIM2          Absent in melanoma 2                                                                            0.85   0.28
  203967_at      CDC6          Cell division cycle 6                                                                           0.77   0.28
  204127_at      RFC3          Replication factor C (activator 1) 3, 38 kDa                                                    0.81   0.28
  204994_at      MX2           Myxovirus (influenza virus) resistance 2 (mouse)                                                0.63   0.28
  210495_x\_at   FN1           Fibronectin 1                                                                                   0.98   0.28
  212464_s\_at   FN1           Fibronectin 1                                                                                   0.95   0.27
  203708_at      PDE4B         Phosphodiesterase 4B, cAMP‐specific                                                             0.78   0.27
  211719_x\_at   FN1           Fibronectin 1                                                                                   0.98   0.27
  202833_s\_at   SERPINA1      Serpin peptidase inhibitor, clade A (alpha‐1 antiproteinase, antitrypsin), member 1             1.03   0.27
  205479_s\_at   PLAU          Plasminogen activator, urokinase                                                                1.02   0.27
  201506_at      TGFBI         Transforming growth factor, beta‐induced, 68 kDa                                                1.12   0.26
  204823_at      NAV3          Neuron navigator 3                                                                              0.94   0.26
  220104_at      ZC3HAV1       Zinc finger CCCH‐type, antiviral 1                                                              0.79   0.26
  213293_s\_at   TRIM22        Tripartite motif containing 22                                                                  0.41   0.26
  222162_s\_at   ADAMTS1       ADAM metallopeptidase with thrombospondin type 1 motif, 1                                       0.90   0.26
  201340_s\_at   ENC1          Ectodermal‐neural cortex 1 (with BTB domain)                                                    0.99   0.25
  201341_at      ENC1          Ectodermal‐neural cortex 1 (with BTB domain)                                                    0.93   0.25
  202628_s\_at   SERPINE1      Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   0.99   0.24
  219148_at      PBK           PDZ‐binding kinase                                                                              0.99   0.24
  202086_at      MX1           Myxovirus (influenza virus) resistance 1, interferon‐inducible protein p78 (mouse)              0.70   0.23
  218039_at      NUSAP1        Nucleolar and spindle‐associated protein 1                                                      0.85   0.23
  201890_at      RRM2          Ribonucleotide reductase M2                                                                     0.89   0.22
  202589_at      TYMS          Thymidylate synthetase                                                                          0.85   0.21
  219691_at      SAMD9         Sterile alpha motif domain containing 9                                                         0.62   0.21
  205552_s\_at   OAS1          2′‐5′‐oligoadenylate synthetase 1, 40/46 kDa                                                    0.54   0.20
  202627_s\_at   SERPINE1      Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   1.01   0.20
  214146_s\_at   PPBP          Proplatelet basic protein (chemokine (C‐X‐C motif) ligand 7)                                    1.26   0.20
  219684_at      RTP4          Receptor (chemosensory) transporter protein 4                                                   0.72   0.20
  219908_at      DKK2          Dickkopf WNT signaling pathway inhibitor 2                                                      0.88   0.19
  218585_s\_at   DTL           Denticleless E3 ubiquitin protein ligase homolog (Drosophila)                                   0.95   0.19
  203596_s\_at   IFIT5         Interferon‐induced protein with tetratricopeptide repeats 5                                     0.77   0.19
  213294_at      EIF2AK2       Eukaryotic translation initiation factor 2‐alpha kinase 2                                       0.75   0.18
  209773_s\_at   RRM2          Ribonucleotide reductase M2                                                                     0.86   0.18
  202869_at      OAS1          2′‐5′‐oligoadenylate synthetase 1, 40/46 kDa                                                    0.54   0.16
  205239_at      AREG          Amphiregulin                                                                                    1.00   0.15
  212977_at      ACKR3         Atypical chemokine receptor 3                                                                   1.06   0.15
  203153_at      IFIT1         Interferon‐induced protein with tetratricopeptide repeats 1                                     0.54   0.14
  201289_at      CYR61         Cysteine‐rich, angiogenic inducer, 61                                                           0.83   0.13
  218943_s\_at   DDX58         DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 58                                                       0.69   0.11
  203595_s\_at   IFIT5         Interferon‐induced protein with tetratricopeptide repeats 5                                     0.75   0.09
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Quantitative real‐time PCR was used to confirm a subset of transcripts identified by the microarray experiments. Care was taken to choose genes that were both increased and decreased by CE treatment as well as those with known biological functions. THP‐1 cells were treated as described above, with the exception that three doses of each extract was examined. As shown in Figure [3](#fsn3374-fig-0003){ref-type="fig"} (top panel), unlike the microarray experiment, the 90MX extract significantly regulated colony‐stimulating factor 2 (CSF2) and cyclin L2 (CCNL2) mRNA accumulation. All genes studied, with the exception of solute carrier family 7A11 (SLC7A11), were significantly regulated by CE, albeit to a different extent and with varying potency (Fig. [3](#fsn3374-fig-0003){ref-type="fig"}, bottom panel). However, in the ATP‐binding cassette, the sub‐family G, member 2 (ABCG2) mRNA was affected only at the highest dose, CSF2, 2′‐5′‐oligoadenylate synthetase 1 (OAS1), metallothionein 1F (MT1F), and CCNL2 mRNA were regulated at the 25 *μ*g/mL dose.

![Expression of selected genes identified as responsive to cranberry extracts in THP‐1 cells. Genes were selected from Table [2](#fsn3374-tbl-0002){ref-type="table-wrap"} to Figure [2](#fsn3374-fig-0002){ref-type="fig"} for validation by real‐time PCR. Cells were treated and RNA extracted as described in Material and Methods. Gene expression following treatment with 90MX or CE (0, 25, 50, 100 *μ*g/mL) is expressed relative to a housekeeping gene (18S) and normalized to vehicle control (DMSO). Asterisks denote significantly different than control (*P* \< 0.05, *n* = 3, bars represent mean and SEM).](FSN3-5-148-g003){#fsn3374-fig-0003}

GO and pathway analysis {#fsn3374-sec-0011}
-----------------------

The list of genes that were significantly regulated by the CE extract in THP‐1 cells (twofold and *P* \< 0.05, 236 genes) were classified according to their functional ontology terms (GO). Several GO biological processes were significantly enriched in these CE‐regulated genes (<http://pantherdb.org>, see Table S2), including immune effector process, response to interferon, cell cycle checkpoint, cell cycle phase, and response to metal ion. The gene expression patterns were further examined to determine if they were consistent with certain diseases and functions (Ingenuity Pathway Analysis; Table [4](#fsn3374-tbl-0004){ref-type="table-wrap"} and Figures S1, S2). Genes regulated by CEs, such as ABCG2, CCNA2, CCNB1, and CDC25A were associated with cell cycle control and DNA repair processes. The majority of the genes in this network were decreased in expression relative to the DMSO‐treated cells. Similarly, several CE‐regulated genes were enriched in the inflammatory response network and most genes, with the exception of IL6, were repressed. Potential mechanisms by which CE regulates genes within these networks is shown in Table [5](#fsn3374-tbl-0005){ref-type="table-wrap"}. Several transcription factors and signaling molecules are implicated, including HGF signaling, PPAR, LXR, or VDR activation and importantly inhibition of inflammatory signaling such as interferon, MAPK, or NFAT activity.

###### 

Gene ontology analysis: top diseases and functions

  ID   Top diseases and functions                                                                   Molecules in network
  ---- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair   ABCG2, alcohol group acceptor phosphotransferase, ALT, ASAH1, AURKA, BUB1, BUB1B, CCNA2, CCNB1, CD163, Cdc2, CDC25A, CDK1, Cyclin B, ENO2, GADD45A, GINS1, HISTONE, Histone H1, Histone h3, HOPX, IL6, MCM4, MT1G, NASP, NCAPG, PRC1, PRPF4B, PTPase, RNA polymerase II, SFPQ, SMC4, SNX10, Sod, TTK
  2    Cell cycle, embryonic development, organismal survival                                       AIM2, APC (complex), ATM/ATR, ATR, CDC6, CDC20, Cdk, Cyclin A, Cyclin D, Cyclin E, DTL, Dynein, E2f, FANCI, GMNN, HERC5, LUC7L3, MAD2L1, MCM10, MELK, NBN, NFkB (complex), NUSAP1, PCNA, PPP4R4, Rb, Rfc, RFC3, RFC4, RPA, RRM2, SKP2, TRIM22, TYMS, UNG
  3    Antimicrobial response, inflammatory response, cell signaling                                2′ 5′ oas, DDX58, DDX60, EIF2AK2, ERK, IFI16, IFI44, IFIH1, IFIT1, IFIT3, IFIT5, Ifn, IFN alpha/beta, IFN Beta, IFN type 1, Ifnar, IRF, ISG15, ISG20, ISGF3, JAK, MT1M, MX1, Oas, OAS1, OAS2, PARP12, RSAD2, STAT4, Stat1‐Stat2, THEMIS2, USP18, XAF1, ZC3HAV1
  4    Nervous system development and function, cancer, organismal injury and abnormalities         ACKR3, ACPP, ADAMTS1, ADCY, ADRB, Alpha catenin, AREG, BNIP3, CAP2, Cg, Creb, DUSP2, EMR2, FGF13, FSH, Gpcr, GPR56, GPR65, Hdac, HRH1, Lh, Mapk, Metalloprotease, MT1F, MT1X, NMDA Receptor, OXTR, Pdgfr, PLC, PVR, SLC7A11, SNAP25, STEAP1, TCF, Vegf
  5    Infectious disease, cell morphology, hair and skin development, and function                 AIF1, Akt, c‐Src, Calcineurin A, Collagen(s), CYR61, Fascin, FCGR2B, FERMT1, Fgf, Fibrin, Fibrinogen, GDF15, Integrin, Integrin alpha 3 beta 1, Integrin alpha 4 beta 1, ITGA1, JINK1/2, KIAA0101, Laminin, Lfa‐1, LRIG1, MAP2K1/2, MT1E, Notch, PBK, PMAIP1, PNISR, PNN, PPIG, SLC4A7, TLR2/TLR4, TRIB3, TRIM5, ZWINT
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Gene ontology analysis: top pathways

  Canonical pathways                                                      *z*‐score   Molecules
  ----------------------------------------------------------------------- ----------- ------------------------------------------------------
  Cell cycle: G2/M DNA damage checkpoint regulation                       1.134       GADD45A, TOP2A, ATR, AURKA, CDK1, SKP2, CCNB1
  HGF signaling                                                           1           MET, FOS, IL6, ELK3, PRKCB
  PPAR signaling                                                          1           IL33, FOS, IL36G, IL1A
  LXR/RXR activation                                                      0.447       IL33, IL36G, IL1A, SERPINA1, IL6
  Activation of IRF by cytosolic pattern recognition receptors            −0.447      IFIH1, IL10, DDX58, IL6, STAT1, ISG15
  PDGF signaling                                                          −0.447      FOS, CAV1, EIF2AK2, STAT1, PRKCB
  IL‐6 signaling                                                          −0.447      IL33, FOS, IL36G, IL1A, IL6
  NF‐*κ*B signaling                                                       −0.447      IL33, IL36G, IL1A, EIF2AK2, PRKCB
  ERK/MAPK signaling                                                      −0.447      FOS, STAT1, ELK3, DUSP2, PRKCB
  Cholecystokinin/gastrin‐mediated signaling                              −0.816      IL33, FOS, IL36G, IL1A, MEF2C, PRKCB
  Toll‐like receptor signaling                                            −1          IL33, FOS, IL36G, IL1A, EIF2AK2
  Growth hormone signaling                                                −1          FOS, IGFBP3, STAT1, PRKCB
  JAK/stat signaling                                                      −1          STAT4, FOS, IL6, STAT1
  TREM1 signaling                                                         −1          IL10, IL6, FCGR2B, CSF2
  Tec kinase signaling                                                    −1          STAT4, FOS, STAT1, PRKCB
  Production of nitric oxide and reactive oxygen species in macrophages   −1          FOS, SERPINA1, STAT1, PRKCB
  Colorectal cancer metastasis signaling                                  −1          FOS, IL6, STAT1, MMP19
  Role of CHK proteins in cell cycle checkpoint control                   −1.342      PCNA, RFC4, ATR, CDK1, CDC25A, RFC3, NBN
  HMGB1 signaling                                                         −1.342      FOS, IL1A, IL6, SERPINE1, CSF2, PLAT
  p38 MAPK signaling                                                      −1.342      IL33, IL36G, IL1A, MEF2C, STAT1
  Aryl hydrocarbon receptor signaling                                     −1.342      CCNA2, FOS, IL1A, ATR, IL6
  Acute phase response signaling                                          −1.414      IL33, FOS, IL36G, IL1A, FN1, SERPINA1, IL6, SERPINE1
  VDR/RXR activation                                                      −2          GADD45A, IGFBP3, CYP27B1, CSF2, PRKCB
  UVA‐induced MAPK signaling                                              −2          FOS, ZC3HAV1, PARP12, STAT1
  Role of NFAT in regulation of the immune response                       −2          FOS, MEF2C, FCGR2B, RCAN2
  Interferon signaling                                                    −2.236      IFIT3, IFIT1, OAS1, MX1, STAT1
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Discussion {#fsn3374-sec-0012}
==========

Several berry fruits, including the American cranberry (*Vaccinium macrocarpon*), have recently received attention as a result of their effects in vitro and their associations with observational studies with lowered risk of some chronic diseases (Zafra‐Stone et al. [2007](#fsn3374-bib-0045){ref-type="ref"}; Blumberg et al. [2013](#fsn3374-bib-0005){ref-type="ref"}). Cranberries, consumed in sauces, juices, dried fruit, or taken as a dietary supplement in powders or extract form, are a rich source of polyphenols that are associated with a variety of biological effects. In vitro studies have demonstrated antibacterial, antiviral, antimutagenic, anticarcinogenic, antitumorigenic, antiangiogenic, anti‐inflammatory, and antioxidant properties (Yan et al. [2002](#fsn3374-bib-0044){ref-type="ref"}; Bagchi et al. [2004](#fsn3374-bib-0002){ref-type="ref"}; Ferguson et al. [2004](#fsn3374-bib-0015){ref-type="ref"}; Seeram et al. [2004](#fsn3374-bib-0032){ref-type="ref"}; Neto [2007](#fsn3374-bib-0030){ref-type="ref"}; Zafra‐Stone et al. [2007](#fsn3374-bib-0045){ref-type="ref"}) (3,7,8). In vivo, animal models reveal that CEs: reduce proinflammatory interleukins (Kim et al. [2011](#fsn3374-bib-0020){ref-type="ref"}); suppress Helicobacter pylori infection (Blumberg et al. [2013](#fsn3374-bib-0005){ref-type="ref"}), and; improve pancreatic *β*‐cell glucose responsiveness and *β*‐cell mass (Zhu et al. [2011](#fsn3374-bib-0047){ref-type="ref"}). The clinical effects of cranberry and their bioactives include: lowering LDL cholesterol and total cholesterol (Basu and Lyons [2012](#fsn3374-bib-0003){ref-type="ref"}); improving markers of endothelial function (Bagchi et al. [2004](#fsn3374-bib-0002){ref-type="ref"}; Dohadwala et al. [2011](#fsn3374-bib-0014){ref-type="ref"}), lowering glycemic responses (Wilson et al. [2010](#fsn3374-bib-0042){ref-type="ref"}), elevating plasma antioxidant capacity (McKay et al. [2015](#fsn3374-bib-0029){ref-type="ref"}); modulation of gastric *Helicobacter pylori* infection (Shmuely et al. [2012](#fsn3374-bib-0033){ref-type="ref"}); reducing biomarkers of metabolic syndrome (Wilson et al. [2010](#fsn3374-bib-0042){ref-type="ref"}; Basu and Lyons [2012](#fsn3374-bib-0003){ref-type="ref"}; Simão et al. [2013](#fsn3374-bib-0034){ref-type="ref"}), and; protecting against urinary tract infections (UTIs) (Foxman et al. [2015](#fsn3374-bib-0017){ref-type="ref"}).

Cranberries are a particularly rich source of phenolic phytochemicals, including phenolic acids (benzoic, hydroxycinnamic, and ellagic acids) and flavonoids (anthocyanins, flavonols, and flavanols), and these bioactive molecules are believed to be associated with the health benefits described above. The major anthocyanins in cranberry are galactosides and arabinosides of cyanidin and peonidin (Neto [2007](#fsn3374-bib-0030){ref-type="ref"}). Anthocyanin content varies widely among cranberry cultivars with averages between 25 and 65 mg per 100 g of ripe fruit at harvest. The primary flavonol in cranberries is quercetin, which exists in several glycosidic forms, and the total flavonol content of cranberry fruit typically in the range of 20--30 mg per 100 g of fresh fruit weight. In comparing the two CEs used in the present study (Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}), 90MX contained higher amount of organic acids while CE had higher quantities of highly bioactive compounds such as phenolic acids, flavonols, and flavanols (see Table [1](#fsn3374-tbl-0001){ref-type="table-wrap"}). More specific, components with a high antioxidant capacity such as chlorogenic acid, epicatechin, and quercetin were found in high concentrations in CE. The total PACs concentration was 18 times higher in CE than 90MX (51,000 vs. 2800 mg/100 g; \[Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}\]). In HepG2 cells, both CEs decreased ROSs and protected the cells from t‐BOOH‐induced cytotoxicity, albeit with CE being much more potent. Interestingly, stress‐related signaling through the JNK pathway by t‐BOOH was not averted by CE, indicating another mechanism such as redox regulation, might be primary in the protection from oxidative stress by CE in HepG2 cells.

The CEs significantly decreased expression of TNF*α*, CAT, and SOD1 mRNA (Fig. [1](#fsn3374-fig-0001){ref-type="fig"}) relative to the vehicle control in LPS‐stimulated THP‐1 cells. In addition, the microarray studies showed mRNA for acute phase response genes (IL33, FOS, IL36G, IL1A, FN1, SERPINA1, SERPINE1) and interferon‐signaling genes (IFIT3, IFIT1, OAS1, MX1, STAT1; Table [4](#fsn3374-tbl-0004){ref-type="table-wrap"}) were decreased in these cells. These responses are consistent with several other studies showing an anti‐oxidant and anti‐inflammatory effect of cranberries and their bioactive molecules, in particular the PACs. In rats fed an atherogenic diet, C‐reactive protein (CRP) and IL‐1*β* were significantly lower in the cranberry powder groups compared to those in control rats (Kim et al. [2011](#fsn3374-bib-0020){ref-type="ref"}). A CE (OptiBerry) significantly inhibited basal MCP‐1 and inducible NF‐*κ*B transcription as well as the inflammatory biomarker IL‐8 in a similar in vivo model (Zafra‐Stone et al. [2007](#fsn3374-bib-0045){ref-type="ref"}). Treatment of Caco‐2 cells with these CEs prevented iron/ascorbate‐mediated lipid peroxidation and counteracted LPS‐mediated inflammation as evidenced by the decrease in proinflammatory cytokines (TNF‐*α* and IL‐6), cyclo‐oxygenase‐2 (COX‐2) and prostaglandin E2 (PGE2, \[Denis et al. [2015](#fsn3374-bib-0012){ref-type="ref"}\]). Networks of genes involved in the antimicrobial and inflammatory responses and infectious disease (Table [3](#fsn3374-tbl-0003){ref-type="table-wrap"}) were identified as being coordinately affected by CE, adding support for the associations seen in observational studies. The moderate increase in IL‐6 mRNA observed in the present studies, in the absence of increases in other proinflammatory markers such as COX‐2 and IL‐1*α*, may be the result of several factors. First, this suggests that CE is not causing generalized oxidative stress since other mRNAs would be coordinately affected. Second, this increase in IL6 mRNA may not be indicative of altered activity due to the small increase observed (2.5‐fold), the fact that protein level of this factor was not examined and IL6‐responsive genes (such as IL1) were not altered. Finally, it is obvious that CE, due to the complex mixture of bioactive molecules, has multiple mechanisms of action.

The mechanism of this anti‐inflammatory effect has not been extensively studied, although PACs from cranberries and other sources have been proposed to act through oxygen free radical scavenging (Li et al. [2001](#fsn3374-bib-0023){ref-type="ref"}) as well as metal chelation (Arola‐Arnal and Bladé [2011](#fsn3374-bib-0001){ref-type="ref"}), a contributor to ROS production. PACs affect the activity of signaling molecules associated with the inflammatory response, including the redox‐sensitive transcription factor NF‐*κ*B (Liu et al. [2014](#fsn3374-bib-0025){ref-type="ref"}), 5′‐AMP activated protein kinase (AMPK)(Cui et al. [2012](#fsn3374-bib-0010){ref-type="ref"}), p38 mitogen‐activated protein kinase (MAPK, \[Dinh et al. [2014](#fsn3374-bib-0013){ref-type="ref"}\]) and JNK (Guha et al. [2013](#fsn3374-bib-0019){ref-type="ref"}; Liu et al. [2014](#fsn3374-bib-0025){ref-type="ref"}). Data presented herein support the premise that CE decreases activity of NF‐*κ*B, p38 MAPK and NFAT in LPS‐challenged macrophages. Quercetin, a polyphenol found in high concentration in CE (400 mg/100 g; \[Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}\]), induces metallothionein (MT) expression by activating the phosphorylation of JNK, p38 and PI3K/Akt as well as by enhancing Nrf2 DNA‐binding activity in HepG2 cells (Weng et al. [2011](#fsn3374-bib-0041){ref-type="ref"}). In CE‐treated THP‐1 cells, MT1E and 1F mRNA were among the most robustly induced transcripts, indicating that similar signaling pathways are affected in this cell line and that CEs may protect against metal‐induced oxidative stress and toxicity.

Several in vitro studies suggest that cranberry bioactives are potential therapeutic agents for the treatment of cancer (Neto [2007](#fsn3374-bib-0030){ref-type="ref"}; Zafra‐Stone et al. [2007](#fsn3374-bib-0045){ref-type="ref"}). For example, CEs and PACs decrease proliferation of the human breast (Ferguson et al. [2004](#fsn3374-bib-0015){ref-type="ref"}; Sun and Liu [2006](#fsn3374-bib-0036){ref-type="ref"}), glioblastoma multiforme (U87), colon (HT‐29), prostate (DU145), and oral cancer cell lines (Seeram et al. [2004](#fsn3374-bib-0032){ref-type="ref"}; Ferguson et al. [2006](#fsn3374-bib-0016){ref-type="ref"}). Cell cycle arrest and apoptosis was induced by a cranberry PAC‐rich extract in human esophageal adenocarcinoma (EAC) cells (Kresty et al. [2008](#fsn3374-bib-0021){ref-type="ref"}) and prostate cells (MacLean et al. [2011](#fsn3374-bib-0026){ref-type="ref"}). Although cell cycle and proliferation was not studied herein, several genes involved in checkpoint control such as PCNA, RFC4, ATR, CDK1, CDC25A, RFC3, and NBN (Tables [3](#fsn3374-tbl-0003){ref-type="table-wrap"}, [5](#fsn3374-tbl-0005){ref-type="table-wrap"}) were induced at the mRNA level by CE in THP‐1 cells. Interestingly, cranberry ethanolic extract (CEE) prevents the DNA damage produced by benzo\[a\]pyrene (B\[a\]P) in an in vivo mouse peripheral blood micronucleus assay (Madrigal‐Santillán et al. [2012](#fsn3374-bib-0027){ref-type="ref"}). Our current study showed that several CE inducible genes are involved in G2/M DNA Damage checkpoint regulation, including GADD45A and CCNB1 (Tables [4](#fsn3374-tbl-0004){ref-type="table-wrap"}, [5](#fsn3374-tbl-0005){ref-type="table-wrap"}).

Taken together, these studies support the role of cranberry and its complex and rich phytochemical composition as an adjuvant for the treatment or prevention of chronic diseases with an inflammatory component. CEs decreased expression of several markers of inflammation and ROS signaling in the human monocyte cell line THP‐1 that had been challenged with LPS. In addition, through the use of comprehensive gene expression analysis, the potential for cranberry or extracts for the prevention of metal‐induced toxicity as well as cancer is supported. A limitation of the studies presented is that they are exclusively in vitro, using surrogate model systems for inflammation and oxidative stress. Although predictive of the potential of CE to affect human health, there must be consideration of availability of the bioactive constituents and the concentration achieved in vivo. In support of an in vivo response and hence bioavailability of active constituents, rats and mice‐fed CEs exhibited reduced CRP, proinflammatory interleukins, and increase NO synthesis (Wang et al. [2012](#fsn3374-bib-0038){ref-type="ref"}; Blumberg et al. [2013](#fsn3374-bib-0005){ref-type="ref"}; Foxman et al. [2015](#fsn3374-bib-0017){ref-type="ref"}). The range of doses of the cranberry phenolic powders was selected according to previous studies showing that concentrations in the *μ*g/mL range with 30--40 *μ*mol/L of cranberry phytochemicals have been found in plasma after cranberry juice intake (Martín et al. [2015](#fsn3374-bib-0028){ref-type="ref"}). Although the identity of the specific cranberry‐derived bioactive molecule or the molecular pathway involved has not been definitively identified, this study supports a wide range of in vitro, animal as well as nutritional invention studies showing this berry have unique and powerful health benefits.
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**Table S1.** Genes significantly regulated by CE (*P* \< 0.05, twofold).

**Table S2.** PANTHER over‐representation test.

**Figure S1.** Cell proliferation network affected by CE. Genes significantly affected by CE were examined by Ingenuity Pathway Analysis (Qiagen). Red filled symbols denotes increased, while green filled symbols denote decreased, expression relative to control (DMSO‐treated cells).

**Figure S2.** Inflammation network affected by CE. See legend to Figure S1.
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